The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Improving infusion therapy management in metastatic breast cancer: Real-world pilot study of a new pharmacy resource.
 
Reshma Mahtani
Consulting or Advisory Role - Agendia; Amgen; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech/Roche; Gilead Sciences; Hologic/Biotheranostics; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Sermonix Pharmaceuticals; Stemline Therapeutics
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Agendia; Amgen; AstraZeneca; bioTheranostics; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Seagen
 
Aditya Bardia
Consulting or Advisory Role - Alyssum; Daiichi Sankyo/Astra Zeneca; Genentech; Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly; Lilly (Inst); Menarini; Menarini (Inst); Merck; Mersana; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health (Inst); Sanofi
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Sara Tolaney
Consulting or Advisory Role - AADi; Ambrx; Artios Biopharmaceuticals; Arvinas; AstraZeneca; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Blueprint Medicines; Bristol-Myers Squibb; Circle Pharma; Cullinan Oncology; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Summit Therapeutics; Systimmune; Tango Therapeutics; Zentalis; Zuellig Pharma; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Sanofi
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences
 
Carolyn Oxencis
No Relationships to Disclose
 
Kelly Valla
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Ilona Dewald
No Relationships to Disclose
 
Samuel Dooyema
No Relationships to Disclose
 
Jeffrey Carter
No Relationships to Disclose
 
Cherilyn Heggen Ladda
No Relationships to Disclose
 
Kelly McKinnon
No Relationships to Disclose